Biotech
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
Discover the preliminary clinical evidence thresholds cell therapies must achieve to secure simultaneous FDA RMAT and Fast Track designations.
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
Following successful Phase 3 trial results, mRNA platforms are emerging as a versatile, rapid tool for training the immune system to target…
-
Why Oncology Trials Chase Surrogate Endpoints the FDA Ignores
An analysis of how trial designs focused on immune response metrics bypass FDA requirements, potentially delaying approvals for lifesaving cancer combinations.
-
Inside AbbVie’s High-Stakes Neuro Portfolio and Pipeline Strategy
Following recent neuro-pharmaceutical acquisitions and drug approvals, we assess AbbVie’s pipeline strategy, financial impact, and key shareholder risks.
-
Nangibotide Targets Acute-on-Chronic Liver Failure With Phase 2 Data Due 2027
Genfit advances TREM-1 modulator into ACLF after prior Phase 2 trials showed safety signals in septic shock and severe COVID-19.
-
Bristol Myers Squibb vs Vertex: Investment Merits Compared Ahead of 2027
Analysis of financial performance and sector trends pits steady value Bristol Myers Squibb against high-growth Vertex Pharmaceuticals for personal finance readers ahead…
-
Inovio’s First FDA Approval Tests Whether DNA Medicines Can Pay Off for Retail Investors
Voceryq’s accelerated approval for a rare throat disease gives the Plymouth Meeting biotech its first product revenue, but confirmatory trials and a…
-
GSK to Nearly Double Cancer Drugs in Trials as It Rebuilds Oncology Ahead of HIV Patent Cliff
Amidst looming patent expirations for HIV blockbusters, GSK is aggressively expanding its oncology pipeline, aiming to double late-stage cancer drug studies by…
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
Phase 1 trial of OSK gene therapy in three glaucoma patients finds no serious side effects and preliminary visual field improvements at…
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
The FDA’s August 2026 approval of iberdomide introduces a new class of cancer drugs for patients with relapsed or refractory multiple myeloma.
-
How Liquid Biopsy Is Transforming Cancer Monitoring and Early Detection Strategies
Non-invasive blood tests are moving beyond niche use to become vital tools for tracking treatment response, detecting recurrence, and screening for cancer.
-
European Regulators Back Breakthrough Pancreatic Cancer Drug Rasonque
The EMA has recommended approval for daraxonrasib, a daily pill that doubles survival rates for patients with metastatic pancreatic adenocarcinoma.
-
How a Hidden Fat-Sensing Protein Could Unlock Immunotherapy for Deadly Colorectal Cancers
A new study reveals how tweaking a single molecular switch in immune cells could turn ‘untreatable’ tumors into immunotherapy responders—without headlines.
-
How Texas’ $6B CPRIT Outpaces NIH in Speeding Cancer Breakthroughs
The state’s aggressive funding model recruits top researchers and accelerates treatments—while federal grants face slower bureaucratic hurdles.
-
Zanidatamab’s Dual-Targeting Design Offers Alternative To Trastuzumab Deruxtecan
Zanidatamab’s unique mechanism and clinical data show promise for HER2-positive cancer treatment
-
Stanford-Developed Orca-T Wins FDA Approval as First Regulatory T Cell Therapy for Blood Cancer Transplants
STANFORD, October 10 — Stanford Medicine administered the world’s first commercial dose of Orca-T on October 7, 2026, marking the therapy’s debut…
-
Academic Pioneers to Pharma Giants Drive CAR-T Therapy
PHILADELPHIA, July 7, 2026 — Dr. Carl June, director of the Center for Cellular Immunotherapies at the University of Pennsylvania, is widely…
-
ALS Patient Improves, Still Works as Physician After RNA Therapy
BETHESDA, September 19 — A man with a rare, inherited form of amyotrophic lateral sclerosis has become the first person to receive…
-
Zelig Eshhar’s 1989 CAR Idea and CRISPR Therapeutics’ Off-the-Shelf Zugo-cel Lymphoma Results
BOSTON, July 14 — A new chapter in the fight against cancer is unfolding, and it involves editing a patient’s own immune…
-
Alzheimer’s Amyloid Beta Explained: How Plaques Form and Two New Blood Tests Detect Them
NEW YORK, July 16 — For the millions of families touched by Alzheimer’s disease, the science can feel impossibly distant. But behind…
-
Ernexa Plans Fourth-Quarter First-in-Human Trial of ERNA-101 in Ovarian Cancer
SAN FRANCISCO, July 15 — Ernexa Therapeutics, a biotechnology company operating in the U.S. healthcare sector, is preparing to advance its lead…
-
Ernexa Moves ERNA-101 Into GMP Manufacturing Ahead of Planned IND Filing
KARACHI, July 15 — Ernexa Therapeutics is moving toward a planned first-in-human Phase 1 study for its lead cancer candidate, ERNA-101, though…
-
ERNA-101 Platform Targets Cancer with Differentiated Therapy
NEW YORK, July 15 — A new targeted cancer therapy platform is moving toward its first human trials, offering a potential advance…
-
Ernexa Plans IND Filing in Q3 and Ovarian Cancer Trial in Q4 2026
NEW YORK, July 15 — Ernexa Therapeutics is moving its lead candidate ERNA-101 toward a first-in-human Phase 1 study, with the trial…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992